Crinetics Pharmaceuticals, Inc.
CRNX
$34.47
-$0.57-1.63%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 0.00 | -- | 399.00K | 640.00K | 0.00 |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 0.00 | -- | 399.00K | 640.00K | 0.00 |
Cost of Revenue | 66.57M | 61.91M | 58.34M | 53.34M | 45.58M |
Gross Profit | -66.57M | -61.91M | -57.95M | -52.70M | -45.58M |
SG&A Expenses | 28.18M | 25.89M | 24.84M | 20.83M | 17.08M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 94.75M | 87.80M | 83.18M | 74.17M | 62.66M |
Operating Income | -94.75M | -87.80M | -82.78M | -73.53M | -62.66M |
Income Before Tax | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -80.60M | -76.83M | -74.06M | -66.93M | -60.10M |
EBIT | -94.75M | -87.80M | -82.78M | -73.53M | -62.66M |
EBITDA | -93.96M | -87.03M | -82.03M | -73.06M | -62.40M |
EPS Basic | -0.88 | -0.96 | -0.94 | -0.93 | -0.90 |
Normalized Basic EPS | -0.55 | -0.60 | -0.59 | -0.58 | -0.56 |
EPS Diluted | -0.88 | -0.96 | -0.94 | -0.93 | -0.90 |
Normalized Diluted EPS | -0.55 | -0.60 | -0.59 | -0.58 | -0.56 |
Average Basic Shares Outstanding | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M |
Average Diluted Shares Outstanding | 91.49M | 80.09M | 79.01M | 72.29M | 67.15M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |